AHAM Asset Management Bhd (AHAM Capital) has unveiled its latest offering, the AHAM World Series – Biotechnology Fund, aimed at tapping into the dynamic landscape of biotechnology investments.
Positioned as a wholesale feeder growth fund, the AHAM World Series – Biotechnology Fund extends opportunities to investors looking to delve into the flourishing realm of biotechnology ventures. In a statement released by AHAM Capital, the firm disclosed that the fund’s primary focus lies in channeling investments towards the Janus Henderson Horizon Biotechnology Fund, managed by Janus Henderson.
With a strategic investment objective in mind, the fund is set to allocate a minimum of 85% of its net asset value (NAV) to the designated target fund, while up to 15% will be allocated to money market instruments, deposits, and/or cash.
Anton Tan, Chief Executive of Product Solutions & Customer Experience at AHAM Capital, emphasized the pivotal role of biotechnology enterprises in driving scientific breakthroughs, particularly in the realm of genetic research aimed at combatting major diseases. Tan noted significant strides in scientific productivity over the past decade, with the FDA approval rate for drugs witnessing a twofold increase from 121 to 243 in the last 20 years.
“Healthcare spending is on an upward trajectory, propelled by demographic shifts in the US and global aging trends. These enduring factors set a compelling stage for biotechnology investments,” remarked Tan, highlighting the sector’s resilience despite enduring its severest downturn on record. He emphasized the current advantageous valuation of the biotech sector relative to broader market indices, portraying an enticing opportunity for investors.
Andy Acker, Portfolio Manager at Janus Henderson, echoed Tan’s sentiments, underscoring the unprecedented levels of innovation characterizing the biotechnology landscape. Acker attributed this surge in innovation to advancements in life science tools, genetic engineering, and novel therapeutic modalities targeting diseases such as cancer, autoimmune disorders, and rare genetic ailments. He emphasized the potential for investors to unearth groundbreaking therapies and deliver alpha for clients in the process.
AHAM Capital affirmed the suitability of the fund for sophisticated investors seeking capital appreciation over a medium to long-term horizon. The fund, denominated in US dollars, offers three currency classes: USD Class, MYR Class, and MYR Hedged-Class, catering to diverse investor preferences. Minimum investment thresholds stand at $10,000 for the USD class and $30,000 for the MYR class and MYR hedged-class, reflecting the fund’s exclusive positioning in the market.
